Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma

NCT07899996 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07899996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 21, 2025
Completion date
August 1, 2028
Enrollment
160 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • HB0056 Active comparatorHB0056

    HB0056 SC injection every 2/4 weeks .

  • Placebo Placebo comparatorPlacebo

    Placebo

Primary endpoints

Registered primary outcome measures; 3 primary.

  • Part I(Phase Ib): AEs From baseline to week 16

    Incidence of participants with adverse events

  • Part I (Phase Ib): Tss_max From baseline to week 16

    The time required to reach the maximum concentration of HB0056 in the bloodstream after administration at steady state.

  • Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) From baseline to week 12

Lead sponsor's other trials

Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.

Similar trials

Same condition (Asthma) and phase, most recent start first.